KISQALI 600 MG DAILY DOSE

What it is

KISQALI 600 MG DAILY DOSE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ribociclib, under the trade name “KISQALI”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Novartis Pharmaceuticals Corporation.

FDA’s Established Pharmacologic Class for it is Kinase Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $8,691.50 for 30 tablets (30 × $289.71673 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-04-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

The NADAC of all 2 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-04-22. The file is new; the price is not.

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

All 2 NDCs

• 00078-0874-21 · not listed as a package in the FDA directory · $289.71673 per EA · eff. 2026-04-22 filed carried forward
• 00078-0874-63 · Novartis Pharmaceuticals Corporation · $289.71673 per EA · eff. 2026-04-22 filed carried forward

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name ribociclib with KISQALI 600 MG DAILY DOSE.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22, 2026-07-22 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $289.71673 per EA filed.

Of the 20 other products in FDA’s Kinase Inhibitor class priced per EA, 2 have a higher middle NADAC price and 18 a lower one. The one in the middle is NINTEDANIB ESYLATE 150 MG CAP, at $13.45627 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $8,905.21 for 30 tablets, at an average of $296.84034 per EA in 2024 (2024-01-01 to 2024-12-31) for “Kisqali” and “Ribociclib Succinate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 52,578 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.